Cargando…

Dysregulation of prostaglandins, leukotrienes and lipoxin A(4) in bronchiectasis

INTRODUCTION: Bronchiectasis is characterised by excessive neutrophilic inflammation. Lipid mediators such as prostaglandins and leukotrienes have crucial roles in the inflammatory response. Further characterisation of these lipids and understanding the interplay of anti-inflammatory and proinflamma...

Descripción completa

Detalles Bibliográficos
Autores principales: Bedi, Pallavi, Ziegler, Kerstin, Whitfield, Phil D, Davidson, Donald, Rossi, Adriano Giorgio, Hill, Adam T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510413/
https://www.ncbi.nlm.nih.gov/pubmed/34789559
http://dx.doi.org/10.1136/thoraxjnl-2020-216475
_version_ 1784797435532410880
author Bedi, Pallavi
Ziegler, Kerstin
Whitfield, Phil D
Davidson, Donald
Rossi, Adriano Giorgio
Hill, Adam T
author_facet Bedi, Pallavi
Ziegler, Kerstin
Whitfield, Phil D
Davidson, Donald
Rossi, Adriano Giorgio
Hill, Adam T
author_sort Bedi, Pallavi
collection PubMed
description INTRODUCTION: Bronchiectasis is characterised by excessive neutrophilic inflammation. Lipid mediators such as prostaglandins and leukotrienes have crucial roles in the inflammatory response. Further characterisation of these lipids and understanding the interplay of anti-inflammatory and proinflammatory lipid mediators could lead to the development of novel anti-inflammatory therapies for bronchiectasis. AIM: The aim of our study was to characterise the lipids obtained from serum and airways in patients with bronchiectasis in the stable state. METHODS: Six healthy volunteers, 10 patients with mild bronchiectasis, 15 with moderate bronchiectasis and 9 with severe bronchiectasis were recruited. All participants had 60 mL of blood taken and underwent a bronchoscopy while in the stable state. Lipidomics was done on serum and bronchoalveolar lavage fluid (BALF). RESULTS: In the stable state, in serum there were significantly higher levels of prostaglandin E(2) (PGE(2)), 15-hydroxyeicosatetranoic acid (15-HETE) and leukotriene B(4) (LTB(4)) in patients with moderate–severe disease compared with healthy volunteers. There was a significantly lower level of lipoxin A(4) (LXA(4)) in severe bronchiectasis. In BALF, there were significantly higher levels of PGE(2), 5-HETE, 15-HETE, 9-hydroxyoctadecadienoic acid and LTB(4) in moderate–severe patients compared with healthy volunteers. In the stable state, there was a negative correlation of PGE(2) and LTB(4) with % predicted forced expiratory volume in 1 s and a positive correlation with antibiotic courses. LXA(4) improved blood and airway neutrophil phagocytosis and bacterial killing in patients with bronchiectasis. Additionally LXA(4) reduced neutrophil activation and degranulation. CONCLUSION: There is a dysregulation of lipid mediators in bronchiectasis with excess proinflammatory lipids. LXA(4) improves the function of reprogrammed neutrophils. The therapeutic efficacy of LXA(4) in bronchiectasis warrants further studies.
format Online
Article
Text
id pubmed-9510413
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-95104132022-09-27 Dysregulation of prostaglandins, leukotrienes and lipoxin A(4) in bronchiectasis Bedi, Pallavi Ziegler, Kerstin Whitfield, Phil D Davidson, Donald Rossi, Adriano Giorgio Hill, Adam T Thorax Bronchiectasis INTRODUCTION: Bronchiectasis is characterised by excessive neutrophilic inflammation. Lipid mediators such as prostaglandins and leukotrienes have crucial roles in the inflammatory response. Further characterisation of these lipids and understanding the interplay of anti-inflammatory and proinflammatory lipid mediators could lead to the development of novel anti-inflammatory therapies for bronchiectasis. AIM: The aim of our study was to characterise the lipids obtained from serum and airways in patients with bronchiectasis in the stable state. METHODS: Six healthy volunteers, 10 patients with mild bronchiectasis, 15 with moderate bronchiectasis and 9 with severe bronchiectasis were recruited. All participants had 60 mL of blood taken and underwent a bronchoscopy while in the stable state. Lipidomics was done on serum and bronchoalveolar lavage fluid (BALF). RESULTS: In the stable state, in serum there were significantly higher levels of prostaglandin E(2) (PGE(2)), 15-hydroxyeicosatetranoic acid (15-HETE) and leukotriene B(4) (LTB(4)) in patients with moderate–severe disease compared with healthy volunteers. There was a significantly lower level of lipoxin A(4) (LXA(4)) in severe bronchiectasis. In BALF, there were significantly higher levels of PGE(2), 5-HETE, 15-HETE, 9-hydroxyoctadecadienoic acid and LTB(4) in moderate–severe patients compared with healthy volunteers. In the stable state, there was a negative correlation of PGE(2) and LTB(4) with % predicted forced expiratory volume in 1 s and a positive correlation with antibiotic courses. LXA(4) improved blood and airway neutrophil phagocytosis and bacterial killing in patients with bronchiectasis. Additionally LXA(4) reduced neutrophil activation and degranulation. CONCLUSION: There is a dysregulation of lipid mediators in bronchiectasis with excess proinflammatory lipids. LXA(4) improves the function of reprogrammed neutrophils. The therapeutic efficacy of LXA(4) in bronchiectasis warrants further studies. BMJ Publishing Group 2022-10 2021-11-17 /pmc/articles/PMC9510413/ /pubmed/34789559 http://dx.doi.org/10.1136/thoraxjnl-2020-216475 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Bronchiectasis
Bedi, Pallavi
Ziegler, Kerstin
Whitfield, Phil D
Davidson, Donald
Rossi, Adriano Giorgio
Hill, Adam T
Dysregulation of prostaglandins, leukotrienes and lipoxin A(4) in bronchiectasis
title Dysregulation of prostaglandins, leukotrienes and lipoxin A(4) in bronchiectasis
title_full Dysregulation of prostaglandins, leukotrienes and lipoxin A(4) in bronchiectasis
title_fullStr Dysregulation of prostaglandins, leukotrienes and lipoxin A(4) in bronchiectasis
title_full_unstemmed Dysregulation of prostaglandins, leukotrienes and lipoxin A(4) in bronchiectasis
title_short Dysregulation of prostaglandins, leukotrienes and lipoxin A(4) in bronchiectasis
title_sort dysregulation of prostaglandins, leukotrienes and lipoxin a(4) in bronchiectasis
topic Bronchiectasis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510413/
https://www.ncbi.nlm.nih.gov/pubmed/34789559
http://dx.doi.org/10.1136/thoraxjnl-2020-216475
work_keys_str_mv AT bedipallavi dysregulationofprostaglandinsleukotrienesandlipoxina4inbronchiectasis
AT zieglerkerstin dysregulationofprostaglandinsleukotrienesandlipoxina4inbronchiectasis
AT whitfieldphild dysregulationofprostaglandinsleukotrienesandlipoxina4inbronchiectasis
AT davidsondonald dysregulationofprostaglandinsleukotrienesandlipoxina4inbronchiectasis
AT rossiadrianogiorgio dysregulationofprostaglandinsleukotrienesandlipoxina4inbronchiectasis
AT hilladamt dysregulationofprostaglandinsleukotrienesandlipoxina4inbronchiectasis